Vida Ventures
Vida Ventures is a life sciences venture firm that builds and funds biomedical companies across stages with a focus on translating innovations into therapies. The firm emphasizes company building, portfolio support and a Fellowship program, and reports a bicoastal presence with approximately $1.8 billion under management. Core principles cited on the site include patient focus, integrity, entrepreneurship, boldness, humility, collaboration and flexibility.
Industries
Nr. of Employees
small (1-50)
Vida Ventures
Boston, Massachusetts, United States, North America
Portfolio
Entered into a strategic collaboration with Eli Lilly to discover and develop anticancer radiopharmaceuticals. (featured on Vida site)
#Oncology / Radiopharmaceuticals
Secured $126 million financing to advance RIPTAC cancer therapies into the clinic for major solid tumors. (featured on Vida site)
#Oncology (RIPTAC therapies)
Launched with an oversubscribed $165 million Series A financing to develop biologics for solid tumors and inflammatory & immunology diseases. (featured on Vida site)
#Biologics / Oncology and Inflammatory & Immunology
Announced a $150 million Series C financing to advance a clinical-stage precision oncology pipeline. (featured on Vida site)
#Precision oncology
Previously announced a $40 million strategic investment from Sanofi. On May 21, 2025, Vigil and Sanofi announced a definitive merger agreement under which Sanofi will acquire Vigil for $8.00 per share in cash at closing, plus a contingent value right of $2.00 per share upon first commercial sale of VG-3927; companies expect closing in third quarter 2025. (featured on Vida site and investor news)
#Neuroscience / Neurodegenerative disease
Announced closing of merger with AVROBIO and a concurrent private placement of $130.7 million. On Jan 30, 2025, Tectonic reported positive interim Phase 1b hemodynamic data for TX45 in Group 2 pulmonary hypertension in HFpEF. (featured on Vida site and company investor release)
#Therapeutic proteins / GPCR-targeted biologics
Entered into a strategic collaboration with Eli Lilly to discover and develop anticancer radiopharmaceuticals. (featured on Vida site)
#Oncology / Radiopharmaceuticals
Secured $126 million financing to advance RIPTAC cancer therapies into the clinic for major solid tumors. (featured on Vida site)
#Oncology (RIPTAC therapies)
Launched with an oversubscribed $165 million Series A financing to develop biologics for solid tumors and inflammatory & immunology diseases. (featured on Vida site)
#Biologics / Oncology and Inflammatory & Immunology
Announced a $150 million Series C financing to advance a clinical-stage precision oncology pipeline. (featured on Vida site)
#Precision oncology
Previously announced a $40 million strategic investment from Sanofi. On May 21, 2025, Vigil and Sanofi announced a definitive merger agreement under which Sanofi will acquire Vigil for $8.00 per share in cash at closing, plus a contingent value right of $2.00 per share upon first commercial sale of VG-3927; companies expect closing in third quarter 2025. (featured on Vida site and investor news)
#Neuroscience / Neurodegenerative disease
Announced closing of merger with AVROBIO and a concurrent private placement of $130.7 million. On Jan 30, 2025, Tectonic reported positive interim Phase 1b hemodynamic data for TX45 in Group 2 pulmonary hypertension in HFpEF. (featured on Vida site and company investor release)
#Therapeutic proteins / GPCR-targeted biologics